Manufacturer: Gnosis S.p.A.
Active ingredient: Fe+++ Lipofer® pyrophosphate & an active metabolite of Folic acid - Quatrefolic®**
Dosage form: Tablets
There are contraindications. Read the drug label and check with your physician before use.
Composition: Fe+++ Lipofer® pyrophosphate & an active metabolite of Folic acid – Quatrefolic®**
Iron pyrophosphate (in the form of microcapsules of Lipofer®*): 30 mg
Folic acid (as an active metabolite Quatrefolic®): 400 µg
Intended use: an additional source of iron and folic acids.
Short description: Vojea contains Lipofer®, micronized microencapsulated iron, and Quatrefolic®, active metabolite of Folic acid. Lipofer® microcapsule technology allows to improve iron absorption and minimize side effects – metallic taste in the mouth, functional disorders of the gastrointestinal tract.
Quatrefolic® has better absorption than ordinary folic acid by 9.7 times.
Recommended to use:
– to the women, planning pregnancy
– during pregnancy and lactation
– for the prevention of anemia in women of reproductive age from the risk group for the development of anemia 1 (heavy menstruation, chronic inflammatory diseases, etc.)
For women planning pregnancy, during pregnancy and lactation, 1 tablet 1 time a day with meals.
It is recommended to consult a doctor before treatment.
Pregnant and lactating women should take dietary supplements on the recommendation and under the supervision of a doctor.
Individual intolerance to dietary supplement components. It is not recommended for persons under 18 years of age.
Adults – 1 tablet a day with meal. Take with enough water. (200-250 ml). Do not exceed the recommended dose. Course of medication – 1 month, with the retreatment if it is recommended by a physician.
I.N. Kononova, Ye.N. Kareva, Yu.E. Dobrokhotova. Quatrefolic®, active metabolite of the 4th generation of folic acid, & Lipofer®, micronized microencapsulated iron: innovative approaches in replenishing folic acid and iron deficiency in women. Literature Review. RMJ. Mother and Child. 2022;5(1):18-27. DOI: 10.32364/2618-8430-2022-5-1-18-27.